Literature DB >> 11342478

High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection.

B J Van Lenten1, A C Wagner, D P Nayak, S Hama, M Navab, A M Fogelman.   

Abstract

BACKGROUND: Viruses have been identified as one of a variety of potential agents that are implicated in atherogenesis. METHODS AND
RESULTS: C57BL/6J mice were killed before or 2, 3, 5, 7, or 9 days after intranasal infection with 10(5) plaque-forming units (pfu) of Influenza A strain WSN/33. Peak infectivity in lungs was reached by 72 hours, and it returned to baseline by 9 days. No viremia was observed at any time. The activities of paraoxonase and platelet-activating factor acetylhydrolase in HDL decreased after infection and reached their lowest levels 7 days after inoculation. The ability of HDL from infected mice to inhibit LDL oxidation and LDL-induced monocyte chemotactic activity in human artery wall cell cocultures decreased with time after inoculation. Moreover, as the infection progressed, LDL more readily induced monocyte chemotaxis. Peak interleukin-6 and serum amyloid A plasma levels were observed at 2 and 7 days after inoculation. HDL apoA-I levels did not change. ApoJ and ceruloplasmin levels in HDL peaked 3 days after infection. Ceruloplasmin remained elevated throughout the time course, whereas apoJ levels decreased toward baseline after the third day.
CONCLUSIONS: We conclude that alterations in the relative levels of paraoxonase, platelet-activating factor acetylhydrolase, ceruloplasmin, and apoJ in HDL occur during acute influenza infection, causing HDL to lose its anti-inflammatory properties.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342478     DOI: 10.1161/01.cir.103.18.2283

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  98 in total

Review 1.  Influenza and cardiovascular disease: is there a causal relationship?

Authors:  Mohammad Madjid; Ibrahim Aboshady; Imran Awan; Silvio Litovsky; S Ward Casscells
Journal:  Tex Heart Inst J       Date:  2004

Review 2.  Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?

Authors:  Kiyoko Uno; Stephen J Nicholls
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

3.  Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.

Authors:  Jonathan D Smith
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

Review 4.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Authors:  Maureen McMahon; Bevra H Hahn; Brian J Skaggs
Journal:  Expert Rev Clin Immunol       Date:  2011-03       Impact factor: 4.473

5.  Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response.

Authors:  Nicolas Venteclef; Jason C Smith; Bryan Goodwin; Philippe Delerive
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

Review 6.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

7.  Peptide Mimetics of Apolipoproteins Improve HDL Function.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Alan M Fogelman
Journal:  J Clin Lipidol       Date:  2007-05       Impact factor: 4.766

Review 8.  Oxidized low-density lipoprotein.

Authors:  Sampath Parthasarathy; Achuthan Raghavamenon; Mahdi Omar Garelnabi; Nalini Santanam
Journal:  Methods Mol Biol       Date:  2010

9.  Influenza virus infection and risk of acute myocardial infarction.

Authors:  Xiu-Ru Guan; Xin Li; Xiao-Min Xin; Li-Xin Jiang; Lan-Ying Cui; Lan-Feng Wang; Hong-Yuan Li
Journal:  Inflammation       Date:  2008-08       Impact factor: 4.092

Review 10.  Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Authors:  Hong-Liang Li; De-Pei Liu; Chih-Chuan Liang
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.